Alkylating Derivatives of Vitamin D Hormone for Prostate Cancer

Abstract

The most significant achievement of this period is the development of a synthetic scheme to produce substantial quantity of our target compound i.e. 1,25- dihydroxyvitamin D3-3-bromoacetate. This is extremely important for the current project and for the future development of this compound for prostate cancer. We have also screened this compound against prostate and kidney cancer cells for its antiproloferative activity. In addition we have developed a mouse xenograft model to test the efficacy of this compound in reducing androgen-sensitive and androgen-insensitive prostate tumors in future studies.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Oct 01, 2006
Accession Number
ADA462093

Entities

People

  • Rahul Ray

Organizations

  • Boston University

Tags

DTIC Thesaurus Topics

  • Androgens
  • Antineoplastic Agents
  • Apoptosis
  • Cell Line
  • Cell Physiological Processes
  • Chemical Synthesis
  • Chemistry
  • Hormones
  • Kidney Cancer
  • Kidney Diseases
  • Neoplasms
  • Prostate
  • Prostate Cancer
  • Standards
  • United States
  • Vitamin D
  • Xenografts

Readers

  • Oncology (Cancer Research).
  • Prostate Cancer Biology.
  • Systems Analysis and Design